{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:21:47Z","timestamp":1793708507272,"version":"4.6.1"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004702","name":"Universit\u00e0 degli Studi di Genova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40265-023-01957-7","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T05:01:47Z","timestamp":1697259707000},"page":"1595-1611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Current Medical Therapy for Adenomyosis: From Bench to Bedside"],"prefix":"10.1007","volume":"83","author":[{"given":"Andrea","family":"Etrusco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4117-6603","authenticated-orcid":false,"given":"Fabio","family":"Barra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Chiantera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bogliolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Evangelisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engin","family":"Oral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Izzotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Venezia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Ceccaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Simone","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,14]]},"reference":[{"issue":"1","key":"1957_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0889-8545(02)00053-0","volume":"30","author":"IM Matalliotakis","year":"2003","unstructured":"Matalliotakis IM, Kourtis AI, Panidis DK. Adenomyosis. Obstet Gynecol Clin North Am. 2003;30(1):63\u201382.","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"3","key":"1957_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2217\/WHE.12.8","volume":"8","author":"G Benagiano","year":"2012","unstructured":"Benagiano G, Brosens I. The endometrium in adenomyosis. Womens Health (Lond). 2012;8(3):301\u201312.","journal-title":"Womens Health (Lond)"},{"issue":"6","key":"1957_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/humupd\/dmab017","volume":"27","author":"SE Bulun","year":"2021","unstructured":"Bulun SE, Yildiz S, Adli M, Wei JJ. Adenomyosis pathogenesis: insights from next-generation sequencing. Hum Reprod Update. 2021;27(6):1086\u201397.","journal-title":"Hum Reprod Update"},{"issue":"2","key":"1957_CR4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejogrb.2011.03.003","volume":"157","author":"SB Larsen","year":"2011","unstructured":"Larsen SB, Lundorf E, Forman A, Dueholm M. Adenomyosis and junctional zone changes in patients with endometriosis. Eur J Obstet Gynecol Reprod Biol. 2011;157(2):206\u201311.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"1957_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.bpobgyn.2006.01.017","volume":"20","author":"P Vercellini","year":"2006","unstructured":"Vercellini P, Vigano P, Somigliana E, Daguati R, Abbiati A, Fedele L. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. 2006;20(4):465\u201377.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"6","key":"1957_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/00006254-200006000-00025","volume":"55","author":"AS Uduwela","year":"2000","unstructured":"Uduwela AS, Perera MA, Aiqing L, Fraser IS. Endometrial-myometrial interface: relationship to adenomyosis and changes in pregnancy. Obstet Gynecol Surv. 2000;55(6):390\u2013400.","journal-title":"Obstet Gynecol Surv"},{"issue":"5","key":"1957_CR7","first-page":"688","volume":"95","author":"M Levgur","year":"2000","unstructured":"Levgur M, Abadi MA, Tucker A. Adenomyosis: symptoms, histology, and pregnancy terminations. Obstet Gynecol. 2000;95(5):688\u201391.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"1957_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jmig.2018.03.012","volume":"25","author":"PR Koninckx","year":"2018","unstructured":"Koninckx PR, Ussia A, Zupi E, Gomel V. Association of endometriosis and adenomyosis: vast literature but scant conclusive data. J Minim Invasive Gynecol. 2018;25(5):745\u20138.","journal-title":"J Minim Invasive Gynecol"},{"issue":"4","key":"1957_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00404-009-1191-0","volume":"280","author":"G Leyendecker","year":"2009","unstructured":"Leyendecker G, Wildt L, Mall G. The pathophysiology of endometriosis and adenomyosis: tissue injury and repair. Arch Gynecol Obstet. 2009;280(4):529\u201338.","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"1957_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.annpat.2021.03.012","volume":"41","author":"PA Just","year":"2021","unstructured":"Just PA, Moret S, Borghese B, Chapron C. Endometriosis and adenomyosis. Ann Pathol. 2021;41(6):521\u201334.","journal-title":"Ann Pathol"},{"issue":"3","key":"1957_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/uog.14806","volume":"46","author":"T Van den Bosch","year":"2015","unstructured":"Van den Bosch T, Dueholm M, Leone FP, Valentin L, Rasmussen CK, Votino A, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015;46(3):284\u201398.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"9","key":"1957_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/13543784.2021.1957830","volume":"30","author":"S Dababou","year":"2021","unstructured":"Dababou S, Garzon S, Lagana AS, Ferrero S, Evangelisti G, Noventa M, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021;30(9):903\u201311.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"1957_CR13","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/jpm13050716","volume":"13","author":"E Feghali","year":"2023","unstructured":"Feghali E, Etrusco A, Haydamous J, Ayed A, Lagana AS, Chiantera V, et al. Concurrent diagnosis of adenomyosis and congenital uterine anomalies: a review. J Pers Med. 2023;13(5):716.","journal-title":"J Pers Med."},{"issue":"5","key":"1957_CR14","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1148\/rg.2018180080","volume":"38","author":"RK Cunningham","year":"2018","unstructured":"Cunningham RK, Horrow MM, Smith RJ, Springer J. Adenomyosis: a sonographic diagnosis. Radiographics. 2018;38(5):1576\u201389.","journal-title":"Radiographics"},{"issue":"3","key":"1957_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.rbmo.2014.11.005","volume":"30","author":"G Benagiano","year":"2015","unstructured":"Benagiano G, Brosens I, Habiba M. Adenomyosis: a life-cycle approach. Reprod Biomed Online. 2015;30(3):220\u201332.","journal-title":"Reprod Biomed Online"},{"key":"1957_CR16","doi-asserted-by":"crossref","unstructured":"ACOG Committee Opinion No. 760: Dysmenorrhea and endometriosis in the adolescent. Obstet Gynecol. 2018;132(6):e249\u2013e58.","DOI":"10.1097\/AOG.0000000000002978"},{"issue":"2\u201303","key":"1957_CR17","first-page":"151","volume":"38","author":"AG Cope","year":"2020","unstructured":"Cope AG, Ainsworth AJ, Stewart EA. Current and future medical therapies for adenomyosis. Semin Reprod Med. 2020;38(2\u201303):151\u20136.","journal-title":"Semin Reprod Med."},{"issue":"16","key":"1957_CR18","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1517\/14656566.2014.953055","volume":"15","author":"I Streuli","year":"2014","unstructured":"Streuli I, Dubuisson J, Santulli P, de Ziegler D, Batteux F, Chapron C. An update on the pharmacological management of adenomyosis. Expert Opin Pharmacother. 2014;15(16):2347\u201360.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1957_CR19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ajog.2017.08.108","volume":"218","author":"FA Oladosu","year":"2018","unstructured":"Oladosu FA, Tu FF, Hellman KM. Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment. Am J Obstet Gynecol. 2018;218(4):390\u2013400.","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"1957_CR20","first-page":"CD001751","volume":"2015","author":"J Marjoribanks","year":"2015","unstructured":"Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;2015(7):CD001751.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1957_CR21","first-page":"CD000400","volume":"9","author":"M Bofill Rodriguez","year":"2019","unstructured":"Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;9(9):CD000400.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1957_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ajog.2015.07.044","volume":"214","author":"LD Bradley","year":"2016","unstructured":"Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. 2016;214(1):31\u201344.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"1957_CR23","first-page":"970","volume":"12","author":"V Szegeczki","year":"2022","unstructured":"Szegeczki V, Fazekas L, Kulcsar M, Reglodi D, Torok P, Orlik B, et al. Endometrium as control of endometriosis in experimental research: assessment of sample suitability. Diagn (Basel). 2022;12(4):970.","journal-title":"Diagn (Basel)."},{"issue":"7","key":"1957_CR24","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/j.fertnstert.2011.02.051","volume":"95","author":"MK Mehasseb","year":"2011","unstructured":"Mehasseb MK, Panchal R, Taylor AH, Brown L, Bell SC, Habiba M. Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis. Fertil Steril. 2011;95(7):2228\u201335.","journal-title":"Fertil Steril"},{"issue":"1","key":"1957_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.diii.2012.10.012","volume":"94","author":"G Levy","year":"2013","unstructured":"Levy G, Dehaene A, Laurent N, Lernout M, Collinet P, Lucot JP, et al. An update on adenomyosis. Diagn Interv Imaging. 2013;94(1):3\u201325.","journal-title":"Diagn Interv Imaging"},{"issue":"4","key":"1957_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/rmb2.12408","volume":"20","author":"I Ota","year":"2021","unstructured":"Ota I, Taniguchi F, Ota Y, Nagata H, Wada I, Nakaso T, et al. A controlled clinical trial comparing potent progestins, LNG-IUS and dienogest, for the treatment of women with adenomyosis. Reprod Med Biol. 2021;20(4):427\u201334.","journal-title":"Reprod Med Biol"},{"issue":"3","key":"1957_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.contraception.2010.11.009","volume":"83","author":"J Dinger","year":"2011","unstructured":"Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception. 2011;83(3):211\u20137.","journal-title":"Contraception"},{"issue":"7","key":"1957_CR28","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/jcm9072101","volume":"9","author":"M Zgliczynska","year":"2020","unstructured":"Zgliczynska M, Kocaj K, Szymusik I, Dutsch-Wicherek MM, Ciebiera M, Kosinska-Kaczynska K. Levonorgestrel-releasing intrauterine system as a contraceptive method in nulliparous women: a systematic review. J Clin Med. 2020;9(7):2101.","journal-title":"J Clin Med"},{"issue":"23","key":"1957_CR29","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","volume":"377","author":"LS Morch","year":"2017","unstructured":"Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228\u201339.","journal-title":"N Engl J Med"},{"issue":"10","key":"1957_CR30","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1093\/humrep\/16.10.2103","volume":"16","author":"T Maruo","year":"2001","unstructured":"Maruo T, Laoag-Fernandez JB, Pakarinen P, Murakoshi H, Spitz IM, Johansson E. Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum Reprod. 2001;16(10):2103\u20138.","journal-title":"Hum Reprod"},{"issue":"2","key":"1957_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.fertnstert.2010.10.009","volume":"95","author":"O Ozdegirmenci","year":"2011","unstructured":"Ozdegirmenci O, Kayikcioglu F, Akgul MA, Kaplan M, Karcaaltincaba M, Haberal A, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril. 2011;95(2):497\u2013502.","journal-title":"Fertil Steril"},{"issue":"3","key":"1957_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.contraception.2008.11.004","volume":"79","author":"J Sheng","year":"2009","unstructured":"Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009;79(3):189\u201393.","journal-title":"Contraception"},{"issue":"1","key":"1957_CR33","first-page":"31","volume":"4","author":"N Mansukhani","year":"2013","unstructured":"Mansukhani N, Unni J, Dua M, Darbari R, Malik S, Verma S, et al. Are women satisfied when using levonorgestrel-releasing intrauterine system for treatment of abnormal uterine bleeding? J Midlife Health. 2013;4(1):31\u20135.","journal-title":"J Midlife Health"},{"issue":"7\u20138","key":"1957_CR34","first-page":"285","volume":"58","author":"J Zheng","year":"2013","unstructured":"Zheng J, Xia E, Li TC, Sun X. Comparison of combined transcervical resection of the endometrium and levonorgestrel-containing intrauterine system treatment versus levonorgestrel-containing intrauterine system treatment alone in women with adenomyosis: a prospective clinical trial. J Reprod Med. 2013;58(7\u20138):285\u201390.","journal-title":"J Reprod Med"},{"issue":"4","key":"1957_CR35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1074-3804(05)60158-2","volume":"10","author":"H Maia Jr","year":"2003","unstructured":"Maia H Jr, Maltez A, Coelho G, Athayde C, Coutinho EM. Insertion of mirena after endometrial resection in patients with adenomyosis. J Am Assoc Gynecol Laparosc. 2003;10(4):512\u20136.","journal-title":"J Am Assoc Gynecol Laparosc"},{"issue":"4","key":"1957_CR36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.contraception.2015.05.015","volume":"92","author":"OM Shaaban","year":"2015","unstructured":"Shaaban OM, Ali MK, Sabra AM, Abd El Aal DE. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial. Contraception. 2015;92(4):301\u20137.","journal-title":"Contraception"},{"issue":"4","key":"1957_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajog.2007.10.798","volume":"198","author":"S Cho","year":"2008","unstructured":"Cho S, Nam A, Kim H, Chay D, Park K, Cho DJ, et al. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. Am J Obstet Gyneco. 2008;198(4):373.","journal-title":"Am J Obstet Gyneco"},{"issue":"5","key":"1957_CR38","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1159\/000351431","volume":"22","author":"P Zhang","year":"2013","unstructured":"Zhang P, Song K, Li L, Yukuwa K, Kong B. Efficacy of combined levonorgestrel-releasing intrauterine system with gonadotropin-releasing hormone analog for the treatment of adenomyosis. Med Princ Pract. 2013;22(5):480\u20133.","journal-title":"Med Princ Pract"},{"issue":"3","key":"1957_CR39","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00404-016-4105-y","volume":"294","author":"KH Lee","year":"2016","unstructured":"Lee KH, Kim JK, Lee MA, Ko YB, Yang JB, Kang BH, et al. Relationship between uterine volume and discontinuation of treatment with levonorgestrel-releasing intrauterine devices in patients with adenomyosis. Arch Gynecol Obste. 2016;294(3):561\u20136.","journal-title":"Arch Gynecol Obste"},{"issue":"16","key":"1957_CR40","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.2165\/11206320-000000000-00000","volume":"70","author":"PL McCormack","year":"2010","unstructured":"McCormack PL. Dienogest: a review of its use in the treatment of endometriosis. Drugs. 2010;70(16):2073\u201388.","journal-title":"Drugs"},{"key":"1957_CR41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejogrb.2014.05.031","volume":"179","author":"A Yamanaka","year":"2014","unstructured":"Yamanaka A, Kimura F, Kishi Y, Takahashi K, Suginami H, Shimizu Y, et al. Progesterone and synthetic progestin, dienogest, induce apoptosis of human primary cultures of adenomyotic stromal cells. Eur J Obstet Gynecol Reprod Biol. 2014;179:170\u20134.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"1957_CR42","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.fertnstert.2017.07.021","volume":"108","author":"Y Osuga","year":"2017","unstructured":"Osuga Y, Fujimoto-Okabe H, Hagino A. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. Fertil Steril. 2017;108(4):673\u20138.","journal-title":"Fertil Steril"},{"issue":"4","key":"1957_CR43","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1447-0756.2011.01778.x","volume":"38","author":"C Nagata","year":"2012","unstructured":"Nagata C, Yanagida S, Okamoto A, Morikawa A, Sugimoto K, Okamoto S, et al. Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest. J Obstet Gynaecol Res. 2012;38(4):639\u201344.","journal-title":"J Obstet Gynaecol Res"},{"issue":"8","key":"1957_CR44","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/jog.13674","volume":"44","author":"K Neriishi","year":"2018","unstructured":"Neriishi K, Hirata T, Fukuda S, Izumi G, Nakazawa A, Yamamoto N, et al. Long-term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Res. 2018;44(8):1439\u201344.","journal-title":"J Obstet Gynaecol Res"},{"issue":"9","key":"1957_CR45","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1111\/jog.13406","volume":"43","author":"Y Osuga","year":"2017","unstructured":"Osuga Y, Watanabe M, Hagino A. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis. J Obstet Gynaecol Res. 2017;43(9):1441\u20138.","journal-title":"J Obstet Gynaecol Res"},{"issue":"6","key":"1957_CR46","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00404-015-3755-5","volume":"292","author":"M Fawzy","year":"2015","unstructured":"Fawzy M, Mesbah Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: A prospective clinical trial. Arch Gynecol Obstet. 2015;292(6):1267\u201371.","journal-title":"Arch Gynecol Obstet"},{"issue":"Supplement 1","key":"1957_CR47","doi-asserted-by":"publisher","first-page":"97S","DOI":"10.1097\/01.AOG.0000447438.15298.b4","volume":"123","author":"H Sasa","year":"2014","unstructured":"Sasa H, Imai K, Suzuki A, Sei K, Makimura N, Furuya K. Comparison of low-dose dienogest with low-dose danazol for long-term treatment of adenomyosis. Obstet Gynecol. 2014;123(Supplement 1):97S-S98.","journal-title":"Obstet Gynecol"},{"issue":"7587","key":"1957_CR48","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/bmj.39073.736829.BE","volume":"334","author":"C Farquhar","year":"2007","unstructured":"Farquhar C. Endometriosis. BMJ. 2007;334(7587):249\u201353.","journal-title":"BMJ"},{"key":"1957_CR49","first-page":"CD001017","volume":"2","author":"H Beaumont","year":"2002","unstructured":"Beaumont H, Augood C, Duckitt K, Lethaby A. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev. 2002;2:CD001017.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1957_CR50","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/01.pgp.0000130109.80359.57","volume":"23","author":"K Ueki","year":"2004","unstructured":"Ueki K, Kumagai K, Yamashita H, Li ZL, Ueki M, Otsuki Y. Expression of apoptosis-related proteins in adenomyotic uteri treated with danazol and GnRH agonists. Int J Gynecol Pathol. 2004;23(3):248\u201358.","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"1957_CR51","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0002-9378(11)91433-1","volume":"167","author":"H Ota","year":"1992","unstructured":"Ota H, Maki M, Shidara Y, Kodama H, Takahashi H, Hayakawa M, et al. Effects of danazol at the immunologic level in patients with adenomyosis, with special reference to autoantibodies: A multi-center cooperative study. Am J Obstet Gynecol. 1992;167(2):481\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"1957_CR52","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1093\/humrep\/den208","volume":"23","author":"X Zhang","year":"2008","unstructured":"Zhang X, Yuan H, Deng L, Hu F, Ma J, Lin J. Evaluation of the efficacy of a danazol-loaded intrauterine contraceptive device on adenomyosis in an ICR mouse model. Hum Reprod. 2008;23(9):2024\u201330.","journal-title":"Hum Reprod"},{"issue":"1","key":"1957_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1447-0756.1990.tb00207.x","volume":"16","author":"M Igarashi","year":"1990","unstructured":"Igarashi M. A new therapy for pelvic endometriosis and uterine adenomyosis: Local effect of vaginal and intrauterine danazol application. Asia Oceania J Obstet Gynaecol. 1990;16(1):1\u201312.","journal-title":"Asia Oceania J Obstet Gynaecol"},{"issue":"2","key":"1957_CR54","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0015-0282(00)00624-5","volume":"74","author":"M Igarashi","year":"2000","unstructured":"Igarashi M, Abe Y, Fukuda M, Ando A, Miyasaka M, Yoshida M, et al. Novel conservative medical therapy for uterine adenomyosis with a danazol-loaded intrauterine device. Fertil Steril. 2000;74(2):412\u20133.","journal-title":"Fertil Steril"},{"issue":"4","key":"1957_CR55","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.fertnstert.2008.08.017","volume":"92","author":"S Luisi","year":"2009","unstructured":"Luisi S, Razzi S, Lazzeri L, Bocchi C, Severi FM, Petraglia F. Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age. Fertil Steril. 2009;92(4):1351\u20134.","journal-title":"Fertil Steril"},{"issue":"3","key":"1957_CR56","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000292410","volume":"39","author":"T Takebayashi","year":"1995","unstructured":"Takebayashi T, Fujino Y, Umesaki N, Ogita S. Danazol suspension injected into the uterine cervix of patients with adenomyosis and myoma. Preliminary study. Gynecol Obstet Invest. 1995;39(3):207\u201311.","journal-title":"Gynecol Obstet Invest"},{"issue":"3","key":"1957_CR57","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S0015-0282(03)00794-5","volume":"80","author":"P Vercellini","year":"2003","unstructured":"Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril. 2003;80(3):560\u20133.","journal-title":"Fertil Steril"},{"issue":"5","key":"1957_CR58","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/09513590802005562","volume":"24","author":"AE Schindler","year":"2008","unstructured":"Schindler AE. Non-contraceptive use of hormonal contraceptives. Gynecol Endocrinol. 2008;24(5):235\u20136.","journal-title":"Gynecol Endocrinol"},{"key":"1957_CR59","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/IJWH.S45093","volume":"5","author":"H Maia Jr","year":"2013","unstructured":"Maia H Jr, Haddad C, Pinheiro N, Casoy J. The effect of oral contraceptives on aromatase and Cox-2 expression in the endometrium of patients with idiopathic menorrhagia or adenomyosis. Int J Womens Health. 2013;5:293\u20139.","journal-title":"Int J Womens Health."},{"issue":"2","key":"1957_CR60","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jsxm.2021.11.015","volume":"19","author":"AM Alcalde","year":"2022","unstructured":"Alcalde AM, Mart\u00ednez-Zamora M\u00c1, Gracia M, Ros C, Rius M, Castelo-Branco C, et al. Assessment of quality of life, sexual quality of life, and pain symptoms in deep infiltrating endometriosis patients with or without associated adenomyosis and the influence of a flexible extended combined oral contraceptive regimen: Results of a prospective, observational study. J Sex Med. 2022;19(2):311\u20138.","journal-title":"J Sex Med"},{"issue":"2","key":"1957_CR61","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ijgo.13600","volume":"154","author":"AI Hassanin","year":"2021","unstructured":"Hassanin AI, Youssef AA, Yousef AM, Ali MK. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: a randomized clinical trial. Int J Gynaecol Obstet. 2021;154(2):263\u20139.","journal-title":"Int J Gynaecol Obstet"},{"issue":"9","key":"1957_CR62","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/17425255.2020.1789591","volume":"16","author":"L Della Corte","year":"2020","unstructured":"Della Corte L, Barra F, Mercorio A, Evangelisti G, Rapisarda AMC, Ferrero S, et al. Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis. Expert Opin Drug Metab Toxicol. 2020;16(9):759\u201368.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3 Pt 2","key":"1957_CR63","first-page":"538","volume":"78","author":"DR Grow","year":"1991","unstructured":"Grow DR, Filer RB. Treatment of adenomyosis with long-term GnRH analogues: a case report. Obstet Gynecol. 1991;78(3 Pt 2):538\u20139.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"1957_CR64","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1600-0412.2012.01350.x","volume":"91","author":"AM Badawy","year":"2012","unstructured":"Badawy AM, Elnashar AM, Mosbah AA. Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstet Gynecol Scand. 2012;91(4):489\u201395.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"1957_CR65","first-page":"1","volume":"15","author":"S Akira","year":"2009","unstructured":"Akira S, Mine K, Kuwabara Y, Takeshita T. Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis. Med Sci Monit. 2009;15(1):1\u20134.","journal-title":"Med Sci Monit"},{"issue":"1","key":"1957_CR66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1056\/NEJMoa1700089","volume":"377","author":"HS Taylor","year":"2017","unstructured":"Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of endometriosis-associated pain with elagolix, an oral GNRH antagonist. N Engl J Med. 2017;377(1):28\u201340.","journal-title":"N Engl J Med"},{"key":"1957_CR67","doi-asserted-by":"publisher","first-page":"e00484","DOI":"10.1016\/j.crwh.2023.e00484","volume":"37","author":"M Barseghyan","year":"2023","unstructured":"Barseghyan M, Theisen JG, Wang C, Gavrilova-Jordan L. Changes in adenomyosis following elagolix vs leuprolide treatment in a patient with pelvic pain and infertility: a case report. Case Rep Womens Health. 2023;37:e00484.","journal-title":"Case Rep Womens Health."},{"issue":"3","key":"1957_CR68","first-page":"338","volume":"2","author":"O Muneyyirci-Delale","year":"2021","unstructured":"Muneyyirci-Delale O, Archer DF, Owens CD, Barnhart KT, Bradley LD, Feinberg E, et al. Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis. F S Rep. 2021;2(3):338\u201346.","journal-title":"F S Rep."},{"issue":"1","key":"1957_CR69","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.rbmo.2021.09.019","volume":"44","author":"J Donnez","year":"2022","unstructured":"Donnez J, Donnez O, Brethous M, Bestel E, Garner E, Charpentier S, et al. Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study. Reprod Biomed Online. 2022;44(1):200\u20133.","journal-title":"Reprod Biomed Online"},{"issue":"24","key":"1957_CR70","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.3390\/jcm10245794","volume":"10","author":"J Donnez","year":"2021","unstructured":"Donnez J, Donnez O, Tourniaire J, Brethous M, Bestel E, Garner E, et al. Uterine adenomyosis treated by linzagolix, an oral gonadotropin-releasing hormone receptor antagonist: a pilot study with a new \u201chit hard first and then maintain\u201d regimen of administration. J Clin Med. 2021;10(24):5794.","journal-title":"J Clin Med"},{"issue":"3","key":"1957_CR71","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.fertnstert.2020.04.017","volume":"114","author":"O Donnez","year":"2020","unstructured":"Donnez O, Donnez J. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. Fertil Steril. 2020;114(3):640\u20135.","journal-title":"Fertil Steril"},{"issue":"1","key":"1957_CR72","doi-asserted-by":"publisher","first-page":"2237121","DOI":"10.1080\/09513590.2023.2237121","volume":"39","author":"K Yamanaka","year":"2023","unstructured":"Yamanaka K, Washio K, Uchida A, Sasagawa Y, Nishimoto M, Yamasaki Y, et al. Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix. Gynecol Endocrinol. 2023;39(1):2237121.","journal-title":"Gynecol Endocrinol"},{"issue":"9","key":"1957_CR73","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/14728222.2016.1180368","volume":"20","author":"A Wagenfeld","year":"2016","unstructured":"Wagenfeld A, Saunders PT, Whitaker L, Critchley HO. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin Ther Targets. 2016;20(9):1045\u201354.","journal-title":"Expert Opin Ther Targets"},{"issue":"11","key":"1957_CR74","doi-asserted-by":"publisher","first-page":"300060522113447","DOI":"10.1177\/03000605221134471","volume":"50","author":"Y Pan","year":"2022","unstructured":"Pan Y, Wu T, Shi H. Distinct clinicopathological features of ovarian endometriosis after long-term exposure to mifepristone. J Int Med Res. 2022;50(11):3000605221134471.","journal-title":"J Int Med Res"},{"issue":"2","key":"1957_CR75","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10616-021-00455-6","volume":"73","author":"X Shen","year":"2021","unstructured":"Shen X, Wang X. The function role and synergic effect of syndecan-1 for mifepristone in uterine leiomyoma. Cytotechnology. 2021;73(2):179\u201387.","journal-title":"Cytotechnology"},{"issue":"4","key":"1957_CR76","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/GCO.0000000000000082","volume":"26","author":"LH Whitaker","year":"2014","unstructured":"Whitaker LH, Williams AR, Critchley HO. Selective progesterone receptor modulators. Curr Opin Obstet Gynecol. 2014;26(4):237\u201342.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"2","key":"1957_CR77","doi-asserted-by":"publisher","first-page":"154","DOI":"10.12891\/ceog15872014","volume":"41","author":"Y Wang","year":"2014","unstructured":"Wang Y, Jiang X, Wang S. The influence of mifepristone to caspase 3 expression in adenomyosis. Clin Exp Obstet Gynecol. 2014;41(2):154\u20137.","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"1","key":"1957_CR78","doi-asserted-by":"publisher","first-page":"101978","DOI":"10.1016\/j.jogoh.2020.101978","volume":"50","author":"P Capmas","year":"2021","unstructured":"Capmas P, Brun JL, Legendre G, Koskas M, Merviel P, Fernandez H. Ulipristal acetate use in adenomyosis: a randomized controlled trial. J Gynecol Obstet Hum Reprod. 2021;50(1):101978.","journal-title":"J Gynecol Obstet Hum Reprod."},{"issue":"2","key":"1957_CR79","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7150\/ijms.39252","volume":"17","author":"X Che","year":"2020","unstructured":"Che X, Wang J, He J, Guo X, Li T, Zhang X. The new application of mifepristone in the relief of adenomyosis-caused dysmenorrhea. Int J Med Sci. 2020;17(2):224\u201333.","journal-title":"Int J Med Sci"},{"issue":"S1","key":"1957_CR80","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/uog.16450","volume":"48","author":"S Ferrero","year":"2016","unstructured":"Ferrero S, Racca A, Tafi E, Scala C, Venturini PL, Leone-Roberti-Maggiore U. OP30.04: changes in the sonographic characteristics of adenomyosis after treatment with ulipristal acetate. Ultrasound Obstetr Gynecol. 2016;48(S1):151.","journal-title":"Ultrasound Obstetr Gynecol"},{"issue":"4","key":"1957_CR81","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/jog.13917","volume":"45","author":"YH Hong","year":"2019","unstructured":"Hong YH, Han SJ, Lee D, Kim SK, Jee BC. Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and\/or adenomyosis. J Obstet Gynaecol Res. 2019;45(4):865\u201370.","journal-title":"J Obstet Gynaecol Res"},{"issue":"3","key":"1957_CR82","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/bcpt.13631","volume":"129","author":"RJ Dinis-Oliveira","year":"2021","unstructured":"Dinis-Oliveira RJ, Vieira DN. Acute liver failure requiring transplantation: a possible link to ulipristal acetate treatment? Basic Clin Pharmacol Toxicol. 2021;129(3):278\u201382.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"1957_CR83","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1210\/clinem\/dgab081","volume":"106","author":"EL Yoon","year":"2021","unstructured":"Yoon EL, Yuk JS. Use of ulipristal acetate and risk of liver disease: a nationwide cohort study. J Clin Endocrinol Metab. 2021;106(6):1773\u201382.","journal-title":"J Clin Endocrinol Metab"},{"key":"1957_CR84","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/nyas.12411","volume":"1317","author":"S Ferrero","year":"2014","unstructured":"Ferrero S, Remorgida V, Maganza C, Venturini PL, Salvatore S, Papaleo E, et al. Aromatase and endometriosis: estrogens play a role. Ann N Y Acad Sci. 2014;1317:17\u201323.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"1957_CR85","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12905-021-01347-9","volume":"21","author":"P Acien","year":"2021","unstructured":"Acien P, Velasco I, Acien M. Anastrozole and levonorgrestrel-releasing intrauterine device in the treatment of endometriosis: a randomized clinical trial. BMC Womens Health. 2021;21(1):211.","journal-title":"BMC Womens Health"},{"key":"1957_CR86","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1477-7827-9-88","volume":"9","author":"S Ferrero","year":"2011","unstructured":"Ferrero S, Venturini PL, Gillott DJ, Remorgida V. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. Reprod Biol Endocrinol. 2011;9:88.","journal-title":"Reprod Biol Endocrinol"},{"issue":"6","key":"1957_CR87","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.fertnstert.2006.09.010","volume":"87","author":"F Kimura","year":"2007","unstructured":"Kimura F, Takahashi K, Takebayashi K, Fujiwara M, Kita N, Noda Y, et al. Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist. Fertil Steril. 2007;87(6):1468.","journal-title":"Fertil Steril"},{"issue":"7","key":"1957_CR88","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1080\/01443615.2017.1308323","volume":"37","author":"T Yanase","year":"2017","unstructured":"Yanase T, Kikuchi A, Sasagawa M, Honma S. Two cases of endometrial cancer arising from adenomyosis during aromatase inhibitors therapy after mastectomy. J Obstet Gynaecol. 2017;37(7):952\u20134.","journal-title":"J Obstet Gynaecol"},{"issue":"2","key":"1957_CR89","first-page":"107","volume":"5","author":"T Mori","year":"1991","unstructured":"Mori T, Kawashima S, Nagasawa H. Induction of uterine adenomyosis by pituitary grafting and retardation of its development by bromocriptine-mesilate (CB-154) in BALB\/c mice. In Vivo. 1991;5(2):107\u20139.","journal-title":"In Vivo"},{"issue":"10","key":"1957_CR90","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/aogs.13632","volume":"98","author":"JK Andersson","year":"2019","unstructured":"Andersson JK, Khan Z, Weaver AL, Vaughan LE, Gemzell-Danielsson K, Stewart EA. Vaginal bromocriptine improves pain, menstrual bleeding and quality of life in women with adenomyosis: a pilot study. Acta Obstet Gynecol Scand. 2019;98(10):1341\u201350.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"1957_CR91","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejogrb.2020.08.040","volume":"254","author":"JK Andersson","year":"2020","unstructured":"Andersson JK, Pozzi Mucelli R, Epstein E, Stewart EA, Gemzell-Danielsson K. Vaginal bromocriptine for treatment of adenomyosis: impact on magnetic resonance imaging and transvaginal ultrasound. Eur J Obstet Gynecol Reprod Biol. 2020;254:38\u201343.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"1957_CR92","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.fertnstert.2018.10.013","volume":"111","author":"PR Koninckx","year":"2019","unstructured":"Koninckx PR, Ussia A, Adamyan L, Wattiez A, Gomel V, Martin DC. Pathogenesis of endometriosis: the genetic\/epigenetic theory. Fertil Steril. 2019;111(2):327\u201340.","journal-title":"Fertil Steril"},{"issue":"11","key":"1957_CR93","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1177\/1933719110377118","volume":"17","author":"N Jichan","year":"2010","unstructured":"Jichan N, Xishi L, Guo SW. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent. Reprod Sci. 2010;17(11):995\u20131005.","journal-title":"Reprod Sci"},{"issue":"18","key":"1957_CR94","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1001\/jama.1979.03290440016012","volume":"241","author":"S Livingston","year":"1979","unstructured":"Livingston S, Pauli LL, Pruce I, Kramer II. Valproic acid in epilepsy. JAMA. 1979;241(18):1892.","journal-title":"JAMA"},{"issue":"10","key":"1957_CR95","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1177\/1933719111404610","volume":"18","author":"X Mao","year":"2011","unstructured":"Mao X, Wang Y, Carter AV, Zhen X, Guo SW. The retardation of myometrial infiltration, reduction of uterine contractility, and alleviation of generalized hyperalgesia in mice with induced adenomyosis by levo-tetrahydropalmatine (l-THP) and andrographolide. Reprod Sci. 2011;18(10):1025\u201337.","journal-title":"Reprod Sci"},{"issue":"7","key":"1957_CR96","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/j.1447-0756.2011.01655.x","volume":"37","author":"X Liu","year":"2011","unstructured":"Liu X, Guo SW. Valproic acid alleviates generalized hyperalgesia in mice with induced adenomyosis. J Obstet Gynaecol Res. 2011;37(7):696\u2013708.","journal-title":"J Obstet Gynaecol Res"},{"issue":"15","key":"1957_CR97","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","volume":"46","author":"RM Nanau","year":"2013","unstructured":"Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46(15):1323\u201338.","journal-title":"Clin Biochem"},{"issue":"1","key":"1957_CR98","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.fertnstert.2006.11.009","volume":"89","author":"X Liu","year":"2008","unstructured":"Liu X, Guo SW. A pilot study on the off-label use of valproic acid to treat adenomyosis. Fertil Steril. 2008;89(1):246\u201350.","journal-title":"Fertil Steril"},{"issue":"10","key":"1957_CR99","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/1933719110373807","volume":"17","author":"L Xishi","year":"2010","unstructured":"Xishi L, Lei Y, Guo SW. Valproic acid as a therapy for adenomyosis: A comparative case series. Reprod Sci. 2010;17(10):904\u201312.","journal-title":"Reprod Sci"},{"issue":"4","key":"1957_CR100","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.fertnstert.2015.08.030","volume":"104","author":"P Vigano","year":"2015","unstructured":"Vigano P, Corti L, Berlanda N. Beyond infertility: obstetrical and postpartum complications associated with endometriosis and adenomyosis. Fertil Steril. 2015;104(4):802\u201312.","journal-title":"Fertil Steril"},{"issue":"9","key":"1957_CR101","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/OGX.0000000000000346","volume":"71","author":"T Harada","year":"2016","unstructured":"Harada T, Khine YM, Kaponis A, Nikellis T, Decavalas G, Taniguchi F. The impact of adenomyosis on women\u2019s fertility. Obstet Gynecol Surv. 2016;71(9):557\u201368.","journal-title":"Obstet Gynecol Surv"},{"issue":"4","key":"1957_CR102","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/1933719118756754","volume":"25","author":"TP Rocha","year":"2018","unstructured":"Rocha TP, Andres MP, Borrelli GM, Abrao MS. Fertility-sparing treatment of adenomyosis in patients with infertility: a systematic review of current options. Reprod Sci. 2018;25(4):480\u20136.","journal-title":"Reprod Sci"},{"issue":"2","key":"1957_CR103","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tjog.2012.04.008","volume":"51","author":"BS Huang","year":"2012","unstructured":"Huang BS, Seow KM, Tsui KH, Huang CY, Lu YF, Wang PH. Fertility outcome of infertile women with adenomyosis treated with the combination of a conservative microsurgical technique and GnRH agonist: long-term follow-up in a series of nine patients. Taiwan J Obstet Gynecol. 2012;51(2):212\u20136.","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"1","key":"1957_CR104","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.rbmo.2022.09.023","volume":"46","author":"M Cozzolino","year":"2023","unstructured":"Cozzolino M, Pellicer N, Galliano D, Pellicer A. Pituitary suppression with GnRH agonists before ART may be insufficient to treat women with severe adenomyosis. Reprod Biomed Online. 2023;46(1):150\u20135.","journal-title":"Reprod Biomed Online"},{"issue":"4","key":"1957_CR105","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1600-0897.2007.00473.x","volume":"57","author":"RG Roussev","year":"2007","unstructured":"Roussev RG, Ng SC, Coulam CB. Natural killer cell functional activity suppression by intravenous immunoglobulin, intralipid and soluble human leukocyte antigen-G. Am J Reprod Immunol. 2007;57(4):262\u20139.","journal-title":"Am J Reprod Immunol"},{"issue":"1","key":"1957_CR106","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jri.2011.12.001","volume":"93","author":"KP Tremellen","year":"2012","unstructured":"Tremellen KP, Russell P. The distribution of immune cells and macrophages in the endometrium of women with recurrent reproductive failure. II: adenomyosis and macrophages. J Reprod Immunol. 2012;93(1):58\u201363.","journal-title":"J Reprod Immunol"},{"key":"1957_CR107","doi-asserted-by":"publisher","first-page":"263349412311812","DOI":"10.1177\/26334941231181258","volume":"17","author":"J Henshaw","year":"2023","unstructured":"Henshaw J, Tremellen K. Intralipid infusion therapy as an adjunct treatment in women experiencing adenomyosis-related infertility. Ther Adv Reprod Health. 2023;17:26334941231181256.","journal-title":"Ther Adv Reprod Health."},{"key":"1957_CR108","doi-asserted-by":"crossref","unstructured":"Liang Z, Yin M, Ma M, Wang Y, Kuang Y. Effect of pretreatment with a levonorgestrel-releasing intrauterine system on IVF and vitrified-warmed embryo transfer outcomes in women with adenomyosis. Reprod Biomed Online. 2019;39(1):111\u2013118.","DOI":"10.1016\/j.rbmo.2019.03.101"},{"issue":"10","key":"1957_CR109","first-page":"CD007618","volume":"10","author":"A Nyachieo","year":"2019","unstructured":"Nyachieo A, Siristatidis CS, Vaidakis D. Nonsteroidal anti-inflammatory drugs for assisted reproductive technology. Cochrane Database Syst Rev. 2019;10(10):CD007618.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1957_CR110","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ajog.2020.01.016","volume":"223","author":"O Yu","year":"2020","unstructured":"Yu O, Schulze-Rath R, Grafton J, Hansen K, Scholes D, Reed SD. Adenomyosis incidence, prevalence and treatment: United States population-based study 2006\u20132015. Am J Obstet Gynecol. 2020;223(1):94.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"1957_CR111","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/aogs.13158","volume":"96","author":"M Dueholm","year":"2017","unstructured":"Dueholm M. Uterine adenomyosis and infertility, review of reproductive outcome after in vitro fertilization and surgery. Acta Obstet Gynecol Scand. 2017;96(6):715\u201326.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"4","key":"1957_CR112","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1358\/dot.2019.55.4.2930713","volume":"55","author":"F Barra","year":"2019","unstructured":"Barra F, Scala C, Ferrero S. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain. Drugs Today (Barc). 2019;55(4):237\u201346.","journal-title":"Drugs Today (Barc)"},{"key":"1957_CR113","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/13543784.2021.1957830","volume":"30","author":"S Dababou","year":"2021","unstructured":"Dababou S, Garzon S, Lagana AS, Ferrero S, Evangelisti G, Noventa M, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021;30:903.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"1957_CR114","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/092986711794480177","volume":"18","author":"F Lumachi","year":"2011","unstructured":"Lumachi F, Luisetto G, Basso SM, Basso U, Brunello A, Camozzi V. Endocrine therapy of breast cancer. Curr Med Chem. 2011;18(4):513\u201322.","journal-title":"Curr Med Chem"},{"issue":"5","key":"1957_CR115","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/13543784.2018.1471135","volume":"27","author":"F Barra","year":"2018","unstructured":"Barra F, Scala C, Mais V, Guerriero S, Ferrero S. Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opin Investig Drugs. 2018;27(5):445\u201358.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"1957_CR116","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.fertnstert.2023.03.021","volume":"119","author":"SW Guo","year":"2023","unstructured":"Guo SW. Various types of adenomyosis and endometriosis: in search of optimal management. Fertil Steril. 2023;119(5):711\u201326.","journal-title":"Fertil Steril"},{"key":"1957_CR117","doi-asserted-by":"publisher","first-page":"103967","DOI":"10.1016\/j.jri.2023.103967","volume":"158","author":"F Barra","year":"2023","unstructured":"Barra F, Perrone U, Ferrero S, Gustavino C, Bogliolo S, Izzotti A. Rituximab for endometriosis: unlikely translatability from oncology due to safety concerns? J Reprod Immunol. 2023;158:103967.","journal-title":"J Reprod Immunol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01957-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01957-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01957-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T06:10:22Z","timestamp":1701497422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01957-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,14]]},"references-count":117,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1957"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01957-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,14]]},"assertion":[{"value":"28 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FB, AE, VC, SF, SB, GE, EO. MP. AI. RV, MC and ASL have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Genova within the CRUI-CARE Agreement.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"F.B., S.F., and A.S.L.: conception and design of the study; A.E. and G.E.: data acquisition and analysis; E.O. and M.C. interpretation of the results; A.E., A.S.L., and F.B. drafting of the manuscript; S.B. supervision and guidance throughout the research process; S.F. and C.V. critical revision of the manuscript for important intellectual content.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}